Amendments to the Claims:

Listing of Claims:

Claim 1 (original): A dispersible tablet comprising Compound I of the formula



or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

Claim 2 (original): A dispersible tablet comprising (a) Compound I or a pharmaceutically acceptable salt thereof, and (b) at least one pharmaceutically acceptable excipient suitable for the preparation of tablets, wherein Compound I or a pharmaceutically acceptable salt thereof is present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

Claim 3 (original): A dispersible tablet comprising an iron-chelating pharmacologically effective amount of Compound I or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

Claim 4 (currently amended): The dispersible tablet according to claim 1[[,]] ~~2 or 3~~ wherein Compound I is in the free acid form.

Claim 5. (currently amended): The dispersible tablet according to ~~any one of claims 1 to 4~~ claim 1 wherein Compound I is in a crystalline form.

Claim 6 (currently amended): The dispersible tablet according to ~~any one of claims 1 to 5~~ claim 1 wherein a lubricant is present in less than 1% in weight based on the total weight of the tablet.

Claim 7 (original): The dispersible tablet according to claim 6 wherein the lubricant is present in less than 0.4% in weight based on the total weight of the tablet.

Claim 8 (currently amended): The dispersible tablet according to ~~any one of claims 1 to 7~~ claim 1 ~~wherein the~~ having a disintegration time ~~of the tablet is~~ of 5 minutes or less.

Claim 9 (currently amended): The dispersible tablet according to ~~any one of claims 1 to 8~~ claim 8 wherein the disintegration time of the tablet is of 3 minutes or less.

Claim 10 (currently amended): The dispersible tablet according to ~~any one of claims 2 to 9~~ claim 2 wherein the pharmaceutically acceptable excipients comprise:

(i) at least one filler in a total amount of about 35 to 55 % in weight based on the total weight of the tablet,

(ii) at least one disintegrant in a total amount of about 10% to 35% in weight based on the total weight of the tablet

(iii) at least one binder in a total amount of about 1.5% to 5% in weight based on the total weight of the tablet,

(iv) at least one surfactant in a total amount of about 0.2% to 1% in weight based on the total weight of the tablet,

(v) at least one glidant in a total amount of about 0.1% to 0.5% in weight based on the total weight of the tablet, and/or

(vi) at least one lubricant in a total amount of less than about 0.4% in weight based on the total weight of the tablet.

Claim 11 (currently amended): The dispersible tablet according to ~~any one of claims 6 to 10~~ claim 10 wherein the lubricant is magnesium stearate.

Claim 12 (currently amended): The dispersible tablet according to ~~anyone of claims 1 to 11~~ claim 10 containing Compound I in its free acid form in an amount of about 100 mg to 600 mg .

Claim 13 (original): A method of administering to a mammal in need of such a treatment a daily dose of 5 to 40 mg/kg of body weight of Compound I as active ingredient.

Claim 14 (currently amended): A process for the preparation of the dispersible tablet according to ~~any one of the preceding claims~~ claim 10, which ~~process~~ comprises:

(i) mixing the Compound I or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in (i);

(iii) mixing the granulates obtained in (ii) with at least one pharmaceutically acceptable excipient to form a mixture; and

(iv) spraying the lubricant on the materials contacting surfaces of pressing tools of the tabletting machine and compressing the mixture obtained in step (iii) to form a tablet.

Claim 15 (original): The process according to claim 14 wherein the lubricant is magnesium stearate.

Claim 16 (new): The dispersible tablet according to claim 3 wherein Compound I is in a free acid form.

Claim 17 (new): The dispersible tablet according to claim 3 wherein Compound I is in a crystalline form.

Claim 18 (new): The dispersible tablet according to claim 3 wherein a lubricant is present in less than 1% in weight based on the total weight of the tablet.

Claim 19 (new): The dispersible tablet according to claim 18 wherein the lubricant is present in less than 0.4% in weight based on the total weight of the tablet.

Claim 20 (new): The dispersible tablet according to claim 2 wherein Compound I is in a free acid form.

Claim 21 (new): The dispersible tablet according to claim 2 wherein Compound I is in a crystalline form.